Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Shanthi Rexaline

YOU WONT BELIEVE: Neogenomics stock gets downgrade after ceo resigns and other negative updates - You Need To See This

NeoGenomics, Inc. (NASDAQ:NEO) shares are getting hammered Tuesday after the cancer diagnostics company announced the abrupt resignation of CEO Mark Mallon and warned of the first-quarter shortfall while also withdrawing its full-year guidance.

The NeoGenomics Analyst: BofA Securities analyst Derik de Bruin downgraded NeoGenomics shares from Buy to Neutral and reduced the price target from $25 to $18.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.